FDA Approves Padcev for Treatment of Advanced Urothelial Cancer
Padcev (enfortumab vedotin-ejfv), a Nectin-4-directed antibody and microtubule inhibitor conjugate, has received accelerated approval for the treatment of locally advanced or metastatic urothe...